Cargando…
Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report
DNA repair mutations (BRCA1 and BRCA2) are found in metastatic castration-resistant prostate cancer (CRPC) patients. Here, we report a case of a 71-year-old male patient with metastatic CRPC along with BRCA2 and PTEN mutations. As per the genomic findings of the Foundation One report, FDA-approved t...
Autores principales: | Julka, Pramod Kumar, Verma, Amit, Gupta, Kush |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036550/ https://www.ncbi.nlm.nih.gov/pubmed/32110220 http://dx.doi.org/10.1159/000505182 |
Ejemplares similares
-
Long-Term 5-Year Response to Pembrolizumab, Bevacizumab, and Capecitabine Regimen in a Metastatic Colon Cancer Patient with MSI-High and KRAS Mutation: Case Report
por: Julka, Pramod Kumar, et al.
Publicado: (2023) -
Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
por: Koguchi, Dai, et al.
Publicado: (2021) -
Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation
por: Kmak, Jamie A., et al.
Publicado: (2020) -
Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
por: Ma, Yi, et al.
Publicado: (2018) -
A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss
por: Myint, Zin W., et al.
Publicado: (2021)